Use of Varenicline for 4-weeks Prior to Quitting: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Use of Varenicline for 4-weeks Prior to Quitting (NCT00789074), a randomized phase 3 study. The primary outcome is Rating of Urges to Smoke 24 Hours and One Week After the Target Quit Date Assessed by Mood and Physical Symptoms Scale.

2. Clinical Question

The study was titled “Use of Varenicline for 4-weeks Prior to Quitting.” Its official title focuses on the effects of an extended period of varenicline use before quitting on post-quitting urges to smoke. The comparison therefore concerns the timing and duration of pre-quit varenicline exposure, rather than a comparison of varenicline with no varenicline throughout the study. Both groups were scheduled to receive varenicline after the pre-quit comparison period: the summary describes a 12-week open-label treatment period in which all participants received varenicline.

The primary outcome was a rating of urges to smoke assessed at 24 hours and one week after the target quit date, with the timeframe recorded as week 4. The primary analysis population is specifically described as those abstinent and with data at 24 hours after the quit date. The record does not clarify how the outcome’s several withdrawal and urge questions were combined into the reported mean. The result should therefore be read as a comparison of the registry’s reported scale measure in that defined population, not as a comparison of all randomized participants or of long-term cessation.

3. Trial Design

The registry describes a completed phase 3, randomized, triple-masked, parallel-group trial sponsored by Queen Mary University of London. Enrollment is listed as 101. The record gives a start of 2009-07 and primary completion of 2009-12. It identifies tobacco dependence and smoking cessation as the conditions under study.

Participants were randomized to one of two pre-quit medication schedules. The varenicline group used varenicline for four weeks before quitting; its arm description specifies 1mg BD. The placebo group used placebo for three weeks and then varenicline for one week before quitting. The brief summary states that after this pre-quit period, all participants would receive varenicline in a 12-week open-label treatment period. Thus the randomized contrast addressed extended versus standard-duration pre-quit use, with a shared subsequent treatment period described in the summary.

Triple masking is the registry’s classification, but the record does not report which roles or individuals were masked, how masking was maintained, or whether masking was assessed. Allocation concealment procedures are not reported in the registry record. Nor does the record give further details about random sequence generation or the protocol’s handling of treatment adherence.

The primary outcome is continuous and reported as a mean with a standard deviation. The registry’s primary analysis population was limited to participants who were abstinent and had outcome data at 24 hours post quit date. The reported group sizes for that outcome are 34 for varenicline and 29 for placebo. These are outcome-specific analysis counts; the record does not explain the relationship between those counts and overall enrollment, or provide a full participant flow. It also does not report the original sample-size justification or the assumptions used to plan enrollment.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: Were abstinent and provided data at 24 hours post quit date

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Rating of Urges to Smoke 24 Hours and One Week After the Target Quit Date Assessed by Mood and Physical Symptoms Scale, measured over 24 hours and 7 days after quit date (week 4).

The primary endpoint is a rating of urges to smoke measured by the Mood and Physical Symptoms Scale. The stated assessment times are 24 hours and seven days after the quit date, recorded in the timeframe as week 4. However, the primary analysis population is defined as participants who were abstinent and had data at 24 hours post quit date. The registry does not clarify whether the reported mean represents the 24-hour assessment alone, a particular scale item, or a combination of the listed items.

The scale description includes tobacco-withdrawal symptoms such as depressed mood, irritability, restlessness, hunger, poor concentration, and sleeping worse than usual. These symptoms use five-point response scales, from Not at all to Extremely. The measure also asks about how often the participant felt an urge to smoke in the last week and how strong those urges were; those questions use six-point scales, with higher values indicating higher craving. The reported unit is units on a scale.

These ratings are used to quantify subjective craving and withdrawal experiences after a quit attempt. A group mean gives an average scale value, while the standard deviation describes variation in individual scores around that mean. The measure is not itself a direct count of cigarettes smoked or a measure of sustained abstinence. Its meaning depends on the scoring and timing used, details that are not fully specified in the registry record. The outcome should therefore be interpreted as a reported symptom-rating comparison in the stated analysis population.

7. Results Posted in the Registry

• Varenicline: mean 2.47 versus 2.88 on control; difference -0.41 (95% CI -0.98 to 0.16), standardized effect d = -0.36; z-test p = 0.155.

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Change in Pre-quit End-expired Carbon Monoxide Reading (CO)

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Varenicline: mean -14.85 versus -7.68 on control; difference -7.17 (95% CI -11.68 to -2.66), standardized effect d = -0.67; z-test p = 0.002.
• Interpretation:
  • The 95% confidence interval excludes no difference, so the mean is statistically lower for Varenicline than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

Change in Pre-quit Cotinine Levels

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Varenicline Pre-treatmemt: mean -184.69 versus -44.73 on control; difference -139.96 (95% CI -196.70 to -83.22), standardized effect d = -1.01; z-test p = <0.001.
• Interpretation:
  • The 95% confidence interval excludes no difference, so the mean is statistically lower for Varenicline Pre-treatmemt than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

Change in Pre-quit Ratings of Cigarette Satisfaction

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Varenicline Pre-treatmemt: mean -1.48 versus -0.84 on control; difference -0.64 (95% CI -1.29 to 0.01), standardized effect d = -0.43; z-test p = 0.055.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Varenicline Pre-treatmemt and the control. The interval gives the range of effects that remain compatible with the data.

The detailed secondary results cover pre-quit end-expired carbon monoxide, cotinine, and cigarette satisfaction. The direction of the posted mean changes favors a larger reduction in carbon monoxide and cotinine in the varenicline pre-treatment group. Their recalculated mean differences are -7.17 ppm for carbon monoxide and -140.0 ng/ml for cotinine, with 95% intervals that exclude zero; the registry’s ANOVA results for both are p < 0.001. For cigarette satisfaction, the mean change was more negative in the varenicline group, but the recalculated interval includes zero. The registry reports p < 0.04 for that ANOVA analysis, while the unadjusted recalculated p-value is 0.055.

This pattern is not the same as the primary post-quit urge result. The primary recalculated interval includes zero, whereas the reported biochemical comparisons have intervals that do not. These endpoints assess different aspects of smoking behavior and exposure at different timeframes, so the secondary findings should not be treated as confirmation of a primary effect on post-quit urges. Nor do biochemical changes alone establish a difference in sustained cessation.

The registry also lists changes in cigarette consumption and MPSS urge and withdrawal ratings as secondary outcomes. Numerical comparisons for those listed outcomes are not reported in the registry record. The secondary analyses are described as ANOVA, but adjustment for testing multiple outcomes is not reported. General statistical principle: examining many outcomes without accounting for multiplicity can make isolated small p-values less persuasive, because the chance of at least one notable result increases across repeated tests. Secondary results are therefore best treated as supportive or exploratory descriptions, not as standalone confirmatory conclusions.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Change in Pre-quit End-expired Carbon Monoxide Reading (CO)
• Change in Pre-quit Cotinine Levels
• Change in Pre-quit Ratings of Cigarette Satisfaction
• Change in Pre-quit Cigarette Consumption
• Change in MPSS Scores of Urges to Smoke and Cigarette Withdrawal Symptoms Throughout the First Four Weeks of Abstinence

9. Statistical Interpretation

10. Statistical Methods Explained

The endpoint is continuous, and the registry reports a mean and standard deviation for each arm. A mean summarizes the central level of the observed ratings. A standard deviation describes how spread out the ratings are around that mean; it is not the uncertainty in the mean itself. The primary reported group summaries are 2.47 with a standard deviation of 1.13 for varenicline and 2.88 with a standard deviation of 1.15 for placebo.

What does the mean difference describe?

The recalculated comparison subtracts the placebo mean from the varenicline mean. The resulting mean difference is -0.41 scale units. A negative value means the posted average was lower for varenicline. This is an unadjusted contrast calculated from the group summaries, not an adjusted estimate from a model that accounts for other participant characteristics. The registry does not report an adjusted effect estimate for this primary outcome.

For a continuous outcome, a mean difference retains the original scale’s units and is often easier to interpret than a standardized effect. Its interpretation depends on the scale’s scoring and construction. Although the registry describes the symptom and urge questions, it does not state exactly how the primary score was assembled. The scale description says higher values correspond to higher craving for the urge questions, but the record does not give a single overall scoring rule for the reported endpoint.

What does the confidence interval add?

A confidence interval describes the range of effect estimates reasonably compatible with the observed data under the assumptions used for the calculation. It communicates precision as well as direction: a narrower interval indicates a more precise estimate, while a wider interval leaves more uncertainty about the size and direction of the effect. The recalculated 95% interval for the primary mean difference includes zero. This means the posted summaries are compatible with no mean difference as well as with differences in either direction. It does not mean that all values in the interval are equally likely, or that there is a 95% probability that the true effect lies in this particular interval.

How should the p-values be read?

The unadjusted recalculated p-value is 0.155, while the registry reports p=0.14 from an ANOVA analysis. A p-value measures how unusual results at least as discrepant as those observed would be under a specified null model and its assumptions. It is not the probability that the null hypothesis is true, and it does not measure the size or clinical importance of an effect. A p-value above a conventional threshold does not prove equivalence or absence of an effect.

ANOVA is a method for comparing means in a model-based framework. The registry identifies ANOVA as the analysis method but does not provide model specifications, covariates, or the exact analysis population for that reported test beyond the primary population description. The recalculation uses only the posted group means, standard deviations, and group sizes. It is therefore a simple unadjusted check, not a reconstruction of every detail of the trial’s statistical model.

Why can group summaries differ from a model result?

A model-based analysis and a comparison reconstructed from summary statistics need not yield identical p-values. Differences can arise from analysis details such as model specification or the observations included, but the registry record does not identify the reason for the small difference in this case. The discrepancy indicator is false. The reported ANOVA result and the unadjusted recalculation should be distinguished rather than treated as interchangeable outputs.

In a parallel-group randomized trial, the comparison concerns outcomes in separate assigned groups. The recalculation treats the reported group summaries as the basis for an unadjusted mean comparison. It does not adjust for baseline values, account for repeated measurements, or reconstruct participant-level data. No such additional adjustment is described in the posted summaries.

Why do dispersion and outcome selection matter?

The standard deviations, 1.13 and 1.15, show that individual ratings varied around the group averages. Variation reduces the precision with which a difference in means can be estimated when group sizes are limited. General statistical principle: greater variability makes it harder to distinguish a group-level shift from the variation among individuals, all else equal.

The primary analysis population was participants abstinent and with data at 24 hours post quit date. That definition matters because the estimate does not represent every randomized participant. The registry does not report how many people were excluded from this endpoint analysis for each reason, how missing outcome values were handled, or whether the analysis followed an intention-to-treat principle. Those omissions limit assessment of selection and missing-data bias.

General statistical principle: when several outcomes are tested, the chance of at least one apparently notable result can increase if no adjustment or prespecified hierarchy is used. The registry lists multiple secondary outcomes and does not report a multiplicity adjustment. Secondary p-values should therefore be interpreted cautiously, particularly when they are considered separately from the primary endpoint.

The endpoint’s different question types and response ranges also warrant care. Withdrawal symptoms use five-point scales, while the urge frequency and strength questions use six-point scales. The record does not say how these items were combined or whether the analysis used a composite or a particular item. That lack of scoring detail limits independent interpretation of a change in the reported mean.

11. Confidence Intervals and Precision

The recalculated primary mean difference is -0.41 scale units, with a 95% confidence interval that crosses zero. The interval therefore includes values consistent with a lower mean in the varenicline group, no mean difference, and a higher mean in the varenicline group. The point estimate alone gives the observed direction, but the interval gives a fuller account of how uncertain the estimated contrast is.

The reported group standard deviations are similar, at 1.13 for varenicline and 1.15 for placebo. They describe the spread of participant ratings, not the precision of the group means. The primary analysis includes 34 participants in the varenicline group and 29 in the placebo group. The confidence interval reflects the uncertainty in the estimated mean difference based on the posted summaries and the calculation assumptions; it should not be confused with the range containing most individual ratings.

The sponsor-reported ANOVA p-value is 0.14, and the unadjusted recalculated p-value is 0.155. Neither p-value conveys the full range of plausible effect sizes. The interval’s inclusion of zero is consistent with the lack of a clear separation at conventional thresholds, but it is not evidence that the groups are equivalent. No equivalence margin or non-inferiority margin is reported in the registry record.

Precision is specific to this endpoint and analysis population. It does not describe the precision of an effect on abstinence, the secondary outcomes, or later smoking behavior. Because the primary analysis is restricted to participants who were abstinent and had outcome data at 24 hours, its interval cannot be generalized automatically to all randomized participants. The original design precision target and sample-size justification are not reported in the registry record.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The planning figures are participants per arm, not total events. They are illustrations based on the observed effect, not the trial’s original sample-size plan. The planning assumptions are a two-sided significance level of 0.05, equal allocation between the two arms, and a normal approximation. Each scenario uses the stated fraction of the observed effect as the effect to detect. The trial’s own original design assumptions are not reported in the registry record.

For the primary outcome, planning for 100% of the observed effect gives 122 participants per arm for 80% power and 163 participants per arm for 90% power. Planning for 75% of the observed effect gives 216 participants per arm for 80% power and 289 participants per arm for 90% power. Planning for 50% of the observed effect gives 485 participants per arm for 80% power and 649 participants per arm for 90% power.

In plain language, 80% power is the planned chance of detecting an effect of the specified size under the calculation assumptions if that effect is the true effect. The 90% power column uses a higher planned chance of detecting that same specified effect. These are design-planning probabilities, not guarantees about what a future study will find. Smaller effects require more participants for the same planned power, which is why the displayed requirements rise as the assumed fraction of the observed effect becomes smaller.

These figures are not observed power. They do not measure the probability that the completed trial found a real effect, and they do not alter the interpretation of the confidence interval or p-value. Because they are anchored to the observed effect, they are illustrations rather than a substitute for the trial’s unreported prospective sample-size justification.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

n is the number of participants in each arm, Δ is the difference in means to detect and σ is the common standard deviation.

Worked calculation for this trial

1. Observed difference Δ = -0.410; pooled standard deviation σ = 1.139.
2. n = 2 × (1.96 + 0.842)² × 1.139² / -0.410² = 121.2, rounded up to 122 participants per arm for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
delta <- -0.41                      # observed difference in means
sigma <- 1.13922392335352                     # pooled standard deviation
n_per_arm <- function(power, frac = 1) {
  ceiling(round(2 * (z_a + qnorm(power))^2 * sigma^2 / (delta * frac)^2, 6))
}
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: n per arm = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(n_per_arm(0.80, f), big.mark = ","), format(n_per_arm(0.90, f), big.mark = ",")))

# Check against R's built-in function (t-based, so very slightly larger)
cat("power.t.test:", round(power.t.test(delta = delta, sd = sigma, power = 0.80)$n, 1), "\n")

# Simulation: exact two-sample t-test using simulated means and variances
set.seed(789074)
n    <- n_per_arm(0.80)
reps <- 20000
m_diff <- rnorm(reps, delta, sigma * sqrt(2 / n))             # difference in sample means
s2     <- sigma^2 * rchisq(reps, 2 * (n - 1)) / (2 * (n - 1))   # pooled sample variance
tstat  <- m_diff / sqrt(s2 * 2 / n)
cat(sprintf("Simulated power at n = %s per arm: %.3f (%d replicates)\n", format(n, big.mark = ","), mean(abs(tstat) > qt(0.975, 2 * (n - 1))), reps))

Output from running the code

100% of observed effect: n per arm = 122 (80% power), 163 (90% power)
 75% of observed effect: n per arm = 216 (80% power), 289 (90% power)
 50% of observed effect: n per arm = 485 (80% power), 649 (90% power)
power.t.test: 122.2 
Simulated power at n = 122 per arm: 0.798 (20000 replicates)

The simulation draws many sets of group means and variances at the planned sample size and counts how often the two-sample t-test rejects the null. It should land close to the target power; at very small required sample sizes it can fall below it, because the normal approximation is rough there.

14. Analyses Reported by the Sponsor

The registry reports an ANOVA comparison between the varenicline and placebo groups, with p=0.14. It does not provide a reported mean difference or confidence interval for that analysis. The recalculated comparison uses the posted means, standard deviations, and group sizes and gives a mean difference of -0.41 scale units, with an unadjusted p-value of 0.155. Its 95% confidence interval includes zero.

The recalculation is a simple unadjusted check of the posted summary statistics. It is not a replacement for the trial’s reported analysis and cannot reproduce model details that the registry does not describe. The difference between p=0.14 and p=0.155 is small, but the values are not identical. The record does not explain the reason for that difference. The discrepancy indicator is false, so there is no flagged inconsistency between the reported and recalculated results.

Both results support a cautious reading: the observed mean was lower in the varenicline group, but the analysis does not establish a clear group difference. The sponsor-reported p-value should be cited as the registry’s analysis result, while the recalculated estimate and interval can help describe the direction and precision that are recoverable from the posted summaries. Neither result establishes equivalence or answers whether extended use affects outcomes beyond the defined analysis population and endpoint.

15. Multiplicity, Missing Data and Analysis Populations

The registry lists several secondary outcomes alongside the primary urge-rating outcome. It reports six outcome measures and six analyses, but a plan for controlling multiplicity is not reported in the registry record. The record does not state whether the primary endpoint was part of a prespecified hierarchy, whether secondary hypotheses were considered confirmatory, or whether any family-wise error or false-discovery procedure was used.

This matters because each separate statistical test creates an opportunity for a result to appear notable by chance when no corresponding effect exists. General statistical principle: the more comparisons considered, the more cautious interpretation of individual unadjusted p-values should be. The secondary p-values are reported without an identified adjustment, so they should not be read as if each were the sole planned test. Their pattern and endpoint context are more informative than treating any one p-value as definitive.

Missing-data handling is not reported in the registry record. The primary endpoint population is described as participants who were abstinent and had data at 24 hours post quit date, but the record does not explain how many randomized participants failed to meet that definition or why. It does not state whether missing scores were imputed, whether incomplete records were excluded, or what assumptions were used about missingness. The outcome-specific group counts alone do not establish the reasons for incomplete data.

The analysis population for the primary result is therefore not an all-randomized population. The record does not identify the primary analysis as intention-to-treat, per-protocol, or another named population, and it does not explain how abstinence status was incorporated beyond defining who contributed to the primary analysis. These omissions limit assessment of potential selection bias and the effect of missing outcomes.

The registry does not report whether interim analyses were conducted, whether stopping rules were used, or whether the analysis plan changed. These are not assumptions that can be filled in from the reported results. The available information supports describing the posted endpoint analyses, but not a full audit of prespecification, missing-data robustness, or multiplicity control.

16. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: musculoskeletal chest pain (2.1%), acute myocardial infarction (1.9%).

The registry reports serious adverse events in one participant at risk in the varenicline pre-treatment group and one participant at risk in the placebo group. The corresponding groups at risk are 53 and 48. These figures describe the reported event counts and at-risk groups; they do not by themselves establish whether an event was caused by the assigned regimen. Deaths are not reported in the registry record.

For other adverse events, the registry lists 34 events in the varenicline pre-treatment group and 22 in the placebo group, with at-risk group counts of 53 and 48, respectively. The record does not provide enough detail to determine event severity, timing, recurrence, or attribution for each event. The counts should not be interpreted as participant-level risks without clarification of the event-counting method.

The most common serious-event terms listed are Musculoskeletal chest pain at 2.1% and Acute Myocardial infarction at 1.9%. The record does not assign those terms to a particular study arm in the information reported. The safety figures are descriptive; the trial record does not provide a formal comparative safety estimate or enough context to infer causation from these counts.

17. What the Result Does, and Does Not, Mean

The primary result describes average urge and withdrawal-related scale ratings for participants who were abstinent and had outcome data at 24 hours after the target quit date. The varenicline group’s reported mean was 2.47, compared with 2.88 in the placebo group. The recalculated mean difference was -0.41 scale units, in the direction of a lower average rating with extended pre-quit varenicline.

The confidence interval includes zero, and the recalculated unadjusted p-value is 0.155; the registry reports p=0.14 from ANOVA. These findings do not establish a clear difference in the primary outcome. They also do not prove the regimens are equivalent or that extended pre-quit treatment has no effect. The estimate has uncertainty in both direction and size, and the record does not report an equivalence or non-inferiority design.

The result does not answer whether the regimens changed the chance of achieving abstinence. The primary analysis was restricted to participants who were abstinent and had outcome data at 24 hours, so it is not a direct comparison of quit rates among all randomized participants. Nor does this endpoint measure sustained cessation, long-term relapse, or smoking behavior beyond the stated assessment period.

The secondary biochemical results show larger reported reductions in the varenicline pre-treatment group, while the satisfaction result is less conclusive in the unadjusted recalculation. These are distinct outcomes and should not be substituted for the primary post-quit rating. With no reported multiplicity adjustment and incomplete numerical reporting for some listed secondary outcomes, the secondary pattern remains descriptive rather than a basis for a broad treatment claim.

In short, the record documents a lower observed primary mean in the extended-regimen group, but the uncertainty does not support a categorical claim that the regimens differ or are the same. Interpretation should remain tied to the specific scale outcome, assessment timing, and selected analysis population recorded for this trial.

18. Why This Trial Matters Statistically

This trial is statistically informative because its comparison isolates a specific treatment-timing question: four weeks of varenicline before quitting versus a placebo-first schedule followed by one week of varenicline. The later open-label period described in the record gives both groups varenicline, so the randomized contrast is focused on the pre-quit schedules rather than on continued use versus no use.

The primary outcome also illustrates why effect estimates and uncertainty should be considered together. The observed mean difference favors a lower urge rating in the varenicline group, but its confidence interval includes zero. A directionally favorable point estimate is not sufficient to establish a reliable group difference; conversely, a p-value that does not indicate a clear difference does not establish equivalence. The interval is central to understanding what the data can and cannot distinguish.

The analysis population is another important statistical feature. The primary result applies to participants who were abstinent and had data at 24 hours, not automatically to everyone randomized. This highlights the difference between an outcome comparison within a defined subset and an overall treatment-assignment effect. Clear reporting of participant flow, missing-data handling, and analysis populations is important for assessing that distinction, and those details are not reported in the registry record.

The secondary outcomes reinforce the need to keep endpoint families distinct. Biochemical changes, satisfaction ratings, and post-quit craving are not interchangeable measures. When multiple secondary tests are considered and multiplicity handling is not reported, isolated p-values deserve less weight than a prespecified primary analysis with its estimate and confidence interval.

Finally, the recalculation demonstrates how posted summary statistics can support a transparent unadjusted estimate while still falling short of a full reconstruction of the trial analysis. The registry’s ANOVA result remains distinct from that recalculation, and the record does not provide enough model detail to reconcile every analytic choice.

19. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The primary result is based on a restricted analysis population: participants who were abstinent and had outcome data at 24 hours after the quit date. The record does not report the reasons other randomized participants were not included in that analysis, or provide a participant-flow account that would allow the selection process to be assessed. This limits how confidently the result can be related to the full randomized population.

The scoring of the primary endpoint is not fully described. The record lists withdrawal-symptom questions on five-point scales and urge questions on six-point scales, but does not explain how those items produced the reported mean. This leaves uncertainty about the exact construct represented by the summary value and complicates interpretation of a difference measured in scale units.

The record describes assessments at 24 hours and seven days after the quit date, while defining the primary analysis population by data at 24 hours. It does not clarify which assessment or scoring rule produced the reported primary mean. This ambiguity is specific to interpreting the timing and content of the primary endpoint.

The numerical secondary results cover only some listed outcomes. Numerical comparisons for cigarette consumption and MPSS urge and withdrawal ratings are not reported in the registry record, limiting assessment of whether the biochemical pattern aligns with other smoking-related measures. Multiplicity handling, missing-data procedures, covariate adjustment, and the original sample-size justification are also not reported.

The trial’s stated open-label period means that the pre-quit randomized comparison is followed by a common treatment period, but the primary result concerns a short post-quit symptom assessment rather than longer-term outcomes. The registry record does not establish whether differences persisted beyond those assessments. These limitations constrain the scope of inference and should not be filled in with assumptions about the protocol or analysis.

20. Related Tutorials

21. Related Statistical Calculators

22. Sources

• ClinicalTrials.gov: Use of Varenicline for 4-weeks Prior to Quitting — NCT00789074.
• Registry record last updated 2013-12-12; status last verified 2013-11.
• Results first posted 2012-06-25.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

23. Record Summary

NCT00789074 is a completed phase 3 randomized, triple-masked, parallel-group trial sponsored by Queen Mary University of London, with enrollment listed as 101. It compared four weeks of pre-quit varenicline with three weeks of placebo followed by one week of varenicline. The brief summary describes a subsequent 12-week open-label period in which all participants received varenicline.

The primary endpoint was a Mood and Physical Symptoms Scale rating of urges to smoke, reported for participants who were abstinent and had data at 24 hours after the quit date. The posted means were 2.47 for varenicline and 2.88 for placebo. The recalculated unadjusted mean difference was -0.41, with a 95% confidence interval including zero and p=0.155. The registry reports an ANOVA result of p=0.14.

The registry reports secondary analyses for biochemical and satisfaction outcomes, alongside other listed outcomes without numerical comparisons in the record. Multiplicity procedures, missing-data handling, the original sample-size justification, and fuller analysis details are not reported in the registry record.